公开(公告)号：US20090197859A1

公开(公告)日：2009-08-06

申请号：US12365305

申请日：2009-02-04

申请人： Elizabeth Martha Collantes ,  Jacob Bradley Schwarz

发明人： Elizabeth Martha Collantes ,  Jacob Bradley Schwarz

IPC分类号： A61K31/496 ,  C07D401/14 ,  A61K31/551 ,  A61P25/18 ,  A61K31/397 ,  C07D243/08

CPC分类号： C07D401/06 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  G11C5/025 ,  G11C5/063 ,  G11C13/0004 ,  G11C13/0023 ,  G11C13/003 ,  G11C2213/72 ,  G11C2213/74 ,  G11C2213/78 ,  G11C2213/79 ,  H01L27/1021

摘要： The present invention relates to novel pyridinyl derivatives of Formula wherein Y, Z, L, R1 through R11, n, m, p, q, t are as defined herein, that are 5-HT receptor ligands, particularly the 5-HT6 subtype, and as such are useful for treating diseases wherein modulation of 5-HT activity is desired. The present invention relates to novel pyridinyl derivatives including their pharmaceutically acceptable salts. The invention also relates to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating diseases of the central nervous system such as schizophrenia.

摘要翻译： 本发明涉及新的式I的吡啶基衍生物，其中Y，Z，L，R 1至R 11，n，m，p，q，t如本文所定义，其为5-HT受体配体，特别是5-HT6亚型， 并且因此可用于治疗其中期望5-HT活性的调节的疾病。 本发明涉及包括其药学上可接受的盐的新的吡啶基衍生物。 本发明还涉及制备用于制备含有此类化合物的药物组合物的中间体的方法，以及用于治疗中枢神经系统疾病如精神分裂症的用途。